Merck’s Vorapaxar CV Outcome Follow-Up Success Not Ready To Become Standard
Cardiovascular and Renal Drugs Advisory Committee says FDA should encourage lost-to-follow-up rates closer to what was seen in Merck’s TRA2P study of vorapaxar, but shouldn’t expect it.
You may also be interested in...
“Clear specific guidance” from the agency would help close the perception gap between what types of data industry thinks FDA wants and what the agency actually expects, according to a summary of a 2012 Institute of Medicine workshop.
Six of 11 members of the Cardiovascular and Renal Drugs Advisory Committee voted against rivaroxaban’s approval for acute coronary syndromes, saying concerns about missing data in the pivotal trial raised doubts about the efficacy results and could not support creating a new standard of care by adding the Factor Xa inhibitor to dual-antiplatelet therapy.
The ticagrelor NDA ignited strong opinions from the cross-discipline team leader about sponsor AstraZeneca’s conduct, drawing a forceful response from the review division director.